KR20200083969A - 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물 - Google Patents

신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물 Download PDF

Info

Publication number
KR20200083969A
KR20200083969A KR1020207007410A KR20207007410A KR20200083969A KR 20200083969 A KR20200083969 A KR 20200083969A KR 1020207007410 A KR1020207007410 A KR 1020207007410A KR 20207007410 A KR20207007410 A KR 20207007410A KR 20200083969 A KR20200083969 A KR 20200083969A
Authority
KR
South Korea
Prior art keywords
acid
subject
neuroprotective composition
neuroprotective
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020207007410A
Other languages
English (en)
Korean (ko)
Inventor
로버트 에이. 뉴먼
오티스 씨. 애딩턴
도날드 씨. 로
린다 에스. 칼텐바흐
Original Assignee
피닉스 바이오테크놀러지 인코포레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피닉스 바이오테크놀러지 인코포레이티드. filed Critical 피닉스 바이오테크놀러지 인코포레이티드.
Publication of KR20200083969A publication Critical patent/KR20200083969A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
KR1020207007410A 2017-09-14 2018-09-04 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물 Abandoned KR20200083969A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558631P 2017-09-14 2017-09-14
US62/558,631 2017-09-14
PCT/US2018/049358 WO2019055245A1 (en) 2017-09-14 2018-10-02 IMPROVED METHOD AND COMPOSITION FOR THE TREATMENT OF TRITERPENE SENSITIVE CONDITIONS, DISEASES OR DISORDERS

Publications (1)

Publication Number Publication Date
KR20200083969A true KR20200083969A (ko) 2020-07-09

Family

ID=65630104

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007410A Abandoned KR20200083969A (ko) 2017-09-14 2018-09-04 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물

Country Status (11)

Country Link
US (2) US10722482B2 (enExample)
EP (1) EP3681477A4 (enExample)
JP (1) JP7370966B2 (enExample)
KR (1) KR20200083969A (enExample)
CN (1) CN111417384A (enExample)
AU (1) AU2018334467B2 (enExample)
CA (1) CA3075023A1 (enExample)
IL (1) IL273161A (enExample)
MX (1) MX2020002884A (enExample)
RU (1) RU2758376C2 (enExample)
WO (2) WO2019055245A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US11331291B2 (en) * 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
CN111417384A (zh) * 2017-09-14 2020-07-14 菲尼克斯生物技术公司 用于治疗神经系统病况的方法和改进的神经保护性组合物
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
WO2021202547A1 (en) * 2020-04-01 2021-10-07 Triterpenoid Therapeutics, Inc. Methods and compositions for treating and preventing viral infection
CN111888367A (zh) * 2020-07-31 2020-11-06 兰州大学 一种萜类化合物在制备增强蛋白酶体活性药物中的应用
US12357641B2 (en) * 2022-10-13 2025-07-15 Hong Kong Baptist University Identification of oleanolic acid and plant extract for glucose-6-phosphate dehydrogenase-related disorders including Bag3opathy

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US922078A (en) 1909-03-01 1909-05-18 Charles Burwell Benson Tongue-depressor.
DK166650B1 (da) 1991-03-15 1993-06-28 Aarhus Oliefabrik As Fedtbaser samt anvendelse af disse i kosmetiske og farmaceutiske emulsionsprodukter
US5977174A (en) 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5985936A (en) 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
DK1079824T3 (da) 1998-05-19 2011-11-21 Res Dev Foundation Triterpen-sammensætninger og fremgangsmåder til anvendelse deraf
ES2308979T3 (es) 1999-04-27 2008-12-16 Forbes Medi-Tech Inc. Procedimiento para la preparacion de una composicion de fitosteroles.
CN1129613C (zh) 1999-12-24 2003-12-03 中国科学院上海药物研究所 夹竹桃花多糖及其制备方法和应用
US20020077350A1 (en) 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Compositions exhibiting synergistic inhibition of the expression and/or activity of clyclooxygenase-2
US6629835B2 (en) * 2000-08-01 2003-10-07 Metaproteomics, Llc Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
CA2418479C (en) 2000-08-18 2007-12-18 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer
DE60204078T2 (de) 2001-04-09 2006-01-26 Loders Croklaan B.V. Konzentrat von Triterpenen
EP1476031A1 (en) 2001-05-11 2004-11-17 University of Ottawa Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
WO2003099011A1 (en) 2002-05-28 2003-12-04 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
KR100751071B1 (ko) * 2003-10-10 2007-08-21 에스케이케미칼주식회사 뇌기능 개선 효과를 갖는 트리테르펜계 화합물
DE602004014974D1 (de) * 2003-12-19 2008-08-21 Lipid Nutrition Bv Verwendung von zusammensetzungen mit oleansäure und ursolsäure zur herstellung eines medikaments zur behandlung von überempfindlichkeit und hyperreaktivität
EP1730163A4 (en) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
US20060135443A1 (en) 2004-10-18 2006-06-22 Bionaut Pharmaceuticals, Inc. Use of Na*/K*-ATPase inhibitors and antagonists thereof
US8022055B2 (en) 2005-02-09 2011-09-20 Dabur Pharma Limited Betulinic acid derivatives
CA2603124A1 (en) 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing tempo
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
WO2006133314A2 (en) 2005-06-08 2006-12-14 Regents Of The University Of Minnesota Synthesis of betulonic and betulinic aldehydes
KR101254938B1 (ko) 2005-06-10 2013-04-16 포라가세이고오교오가부시끼가이샤 신규 트리테르펜산 유도체 및 이를 포함하는 피부 외용제
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
ZA200805703B (en) 2005-12-16 2009-10-28 Panacos Pharmaceuticals Inc Preparation of pharmaceutical salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid
EP1803461A1 (en) 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Therapeutic use of an extract from the leaves of Nerium oleander
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
DE102006020582A1 (de) * 2006-05-03 2007-11-15 Gesellschaft zur Förderung der Krebstherapie e.V. Verfahren zur Herstellung einer triterpensäurehaltigen wässrigen Lösung, triterpensäurehaltige wässrige Lösung und deren Verwendung
WO2008063318A2 (en) 2006-10-12 2008-05-29 The Texas A & M University System And Safe Et Al Betulinic acid, derivatives and analogs thereof and uses therefor
WO2008057420A2 (en) 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
RU2508114C2 (ru) 2007-11-13 2014-02-27 Феникс Байотекнолоджи Инк. Способ определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом
ES2326065B1 (es) 2008-03-28 2010-07-08 Consejo Superior De Investigaciones Cientificas (Csic) Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple.
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
RS58392B1 (sr) 2008-04-18 2019-04-30 Reata Pharmaceuticals Inc Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
HUE033288T2 (en) 2008-04-18 2017-11-28 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives
WO2010028487A1 (en) 2008-09-10 2010-03-18 Université Du Québec À Chicoutimi Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
TW201104501A (en) 2009-07-24 2011-02-01 Asustek Comp Inc Device and method for inputting Chinese character
CN101704872B (zh) 2009-11-23 2012-06-27 张南 23-羟基白桦酸衍生物、其制备方法及应用
US8685469B2 (en) 2009-11-30 2014-04-01 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
RU2582223C2 (ru) 2010-01-11 2016-04-20 Феникс Байотекнолоджи, Инк. Способ лечения неврологических состояний сердечными гликозидами
TWI386415B (zh) 2010-02-02 2013-02-21 Univ Kaohsiung Medical 熊果酸衍生物及其醫藥組合物
KR20170049623A (ko) * 2010-11-22 2017-05-10 피닉스 바이오테크놀러지 인코포레이티드. 네리움 종 또는 테베티아 종의 추출물로 신경학적 병태를 치료하는 방법
TWI410431B (zh) 2010-12-22 2013-10-01 Ind Tech Res Inst 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
US20140221328A1 (en) 2011-01-10 2014-08-07 Bandi Parthasaradhi Reddy Pharmaceutically acceptable salts of novel betulinic acid derivatives
HRP20151212T1 (hr) 2011-01-31 2015-12-04 Bristol-Myers Squibb Company C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
CN102558280B (zh) 2011-11-18 2014-09-17 温州大学 一种30-卤代桦木酸的生产方法
US8987502B2 (en) 2011-12-01 2015-03-24 Hangzhou Bensheng Pharmaceutical Co., Ltd. Oleanolic acid amidate derivatives, preparation methods and uses thereof
DK2786757T3 (da) 2011-12-01 2017-11-20 Hangzhou Bensheng Pharmaceutical Co Ltd 2-substitueret oleanolsyre-derivat, fremgangsmåde til fremstilling af samme, og anvendelse deraf
US20150119373A1 (en) 2012-04-24 2015-04-30 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
KR101889528B1 (ko) 2012-08-14 2018-08-17 넥스올리고(주) 신규한 우르솔릭산 유도체 및 이의 제조 방법
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
LT2892911T (lt) 2012-09-10 2017-11-10 Reata Pharmaceuticals, Inc. Oleanolinės rūgšties c17 heteroarilo dariniai ir jų panaudojimo būdas
TWI630212B (zh) 2012-09-10 2018-07-21 瑞塔醫藥有限責任公司 丁香油素（ｏｌｅａｎｏｌｉｃ ａｃｉｄ）之ｃ１７－烷二基與烯二基衍生物及其使用方法
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
BR112015019590A2 (pt) 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
EP2813221A1 (en) * 2013-06-13 2014-12-17 Natac Biotech, S.L. Combination of pentacyclic triterpenes and hydroxytyrosol and derivatives thereof
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
EP3512524B1 (en) * 2016-09-14 2021-04-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
CN111417384A (zh) * 2017-09-14 2020-07-14 菲尼克斯生物技术公司 用于治疗神经系统病况的方法和改进的神经保护性组合物

Also Published As

Publication number Publication date
EP3681477A4 (en) 2021-06-09
RU2020113349A3 (enExample) 2021-10-14
JP7370966B2 (ja) 2023-10-30
US20190076381A1 (en) 2019-03-14
US20210008017A1 (en) 2021-01-14
RU2758376C2 (ru) 2021-10-28
MX2020002884A (es) 2020-10-05
IL273161A (en) 2020-04-30
US10973785B2 (en) 2021-04-13
AU2018334467A1 (en) 2020-04-16
CA3075023A1 (en) 2019-03-21
AU2018334467B2 (en) 2022-10-20
RU2020113349A (ru) 2021-10-14
US10722482B2 (en) 2020-07-28
WO2019055245A9 (en) 2019-09-26
EP3681477A1 (en) 2020-07-22
CN111417384A (zh) 2020-07-14
WO2019055245A1 (en) 2019-03-21
JP2020534299A (ja) 2020-11-26
WO2020050865A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
AU2018334467B2 (en) Method and improved neuroprotective composition for treating neurological conditions
JP5917413B2 (ja) 強心配糖体で神経学的状態を治療する方法
US10226497B2 (en) Composition for and method of treating neurological conditions
JP6453791B2 (ja) キョウチクトウ属の種又はテベティア属の種の抽出物で神経学的状態を治療する方法
US10383886B2 (en) Method of treating neurological conditions with oleandrin
US10960037B2 (en) Method of treating neurological conditions with extract of Nerium species or Thevetia species
US11331291B2 (en) Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
HK40034649A (en) Method and improved neuroprotective composition for treating neurological conditions
HK1247112B (en) Method of treating neurological conditions with extract of nerium species or thevetia species

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PC1902 Submission of document of abandonment before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000